Publicaciones en colaboración con investigadores/as de Royal Victoria Hospital (12)

2024

  1. Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies

    Journal of neurology, Vol. 271, Núm. 1, pp. 472-485

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

    Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 29, Núm. 7, pp. 875-883

  3. Predictors of treatment switching in the Big Multiple Sclerosis Data Network

    Frontiers in Neurology, Vol. 14

2014

  1. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

    AIDS, Vol. 28, Núm. 16, pp. 2461-2473

2012

  1. The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: Results from the MSBase Registry

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 83, Núm. 3, pp. 305-310

2011

  1. The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: A substudy of the RESOLUTE all comers trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention)

    Journal of the American College of Cardiology, Vol. 57, Núm. 22, pp. 2221-2232

  2. The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: A substudy of the resolute all comers trial

    JACC: Cardiovascular Interventions, Vol. 4, Núm. 4, pp. 432-441

2010

  1. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents

    New England Journal of Medicine, Vol. 363, Núm. 2, pp. 136-146

2006

  1. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplantation recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus

    Liver Transplantation, Vol. 12, Núm. 10, pp. 1464-1472

2005

  1. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: Outcome study with Tolvaptan (EVEREST)

    Journal of Cardiac Failure, Vol. 11, Núm. 4, pp. 260-269

2002

  1. A multicenter study of the tolerability of tirofiban versus placebo in patients undergoing planned intracoronary stent placement

    Clinical Therapeutics, Vol. 24, Núm. 8, pp. 1332-1344